Company Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody.
The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Leon Moulder |
Contact Details
Address: 852 Winter Street, Suite 250 Waltham, Massachusetts 02451 United States | |
| Phone | 857 271 2954 |
| Website | zenasbio.com |
Stock Details
| Ticker Symbol | ZBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001953926 |
| CUSIP Number | 98937L105 |
| ISIN Number | US98937L1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leon Oliver Moulder Jr., M.B.A. | Chief Executive Officer and Chairman of the Board |
| Joseph L. Farmer | Chief Operating Officer and President |
| Jennifer A. Fox | Chief Business Officer and Chief Financial Officer |
| Orlando Oliveira | Chief Commercial Officer |
| Dr. Haley Laken Ph.D. | Chief Scientific Officer |
| Jeffrey Held | Chief Legal Officer |
| Caroline Chevalier | Chief Human Resources Officer |
| Dr. Tanya Z. Fischer M.D., Ph.D. | Head of Research and Development and Chief Medical Officer. |
| Dr. Lisa von Moltke M.D. | Head of Research and Development and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | SCHEDULE 13G | Filing |
| Mar 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2025 | 10-K | Annual Report |
| Feb 5, 2025 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |